A Review of Risk Factors for Predicting Urinary Incontinence after Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the common diseases in middle-aged and elderly men, and its clinical symptoms include storage symptoms, voiding symptoms and post-urination symptoms. Surgery is an important treatment method for benign prostatic hyperplasia. It is suitable for BPH patients with moderate to severe LUTS (Lower Urinary Tract Symptoms) and has significantly affected the quality of life. The surgical methods include transurethral resection of the prostate and transurethral holmium laser enucleation of the prostate. While offering a high chance of cure, it also brings some complications, including postoperative urinary incontinence. This article mainly reviews the urinary incontinence after transurethral prostate surgery in recent years and analyzes its risk factors, and summarizes the experience for further prediction and reduction of the incidence of urinary incontinence.

Epidemiological trends of urinary tract infections,urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019

Background:Urinary tract infections(UTI),urolithiasis,and benign prostatic hyperplasia(BPH)are three of the most common nonmalignant conditions in urology.However,there is still a lack of comprehensive and updated epidemiological data.This study aimed to investigate the disease burden of UTI,urolithiasis,and BPH in 203 countries and territories from 1990 to 2019.Methods:Data were extracted from the Global Burden of Disease 2019,including incident cases,deaths,disabilityadjusted life-years(DALYs)and corresponding age-standardized rate(ASR)from 1990 to 2019.Estimated annual percentage changes(EAPC)were calculated to evaluate the trends of ASR.The associations between disease burden and social development degrees were analyzed using a sociodemographic index(SDI).Results:Compared with 1990,the incident cases of UTI,urolithiasis,and BPH increased by 60.40%,48.57%,and 105.70%in 2019,respectively.The age-standardized incidence rate(ASIR)of UTI increased(EAPC=0.08),while urolithiasis(EAPC=–0.83)and BPH(EAPC=–0.03)decreased from 1990 to 2019.In 2019,the age-standardized mortality rate(ASMR)of UTI and urolithiasis were 3.13/100,000 and 0.17/100,000,respectively.BPH had the largest increase(110.56%)in DALYs in the past three decades,followed by UTI(68.89%)and urolithiasis(16.95%).The burden of UTI was mainly concentrated in South Asia and Tropical Latin America,while the burden of urolithiasis and BPH was recorded in Asia and Eastern Europe.Moreover,the ASIR and SDI of urolithiasis in high-SDI regions from 1990to 2019 were negatively correlated,while the opposite trend was seen in low-SDI regions.In 2019,the ASIR of UTI in females was 3.59 times that of males,while the ASIR of urolithiasis in males was 1.96 times higher than that in females.The incidence was highest in the 30–34,55–59,and 65–69 age groups among the UTI,urolithiasis,and BPH groups,respectively.Conclusions:Over the past three decades,the disease burden has increased for UTI but decreased for urolithiasis and BPH.The allocation of medical resources should be based more on the epidemiological characteristics and geographical distribution of diseases.

Association of Increased Urine Brain Derived Neurotrophic Factor with Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia

Urinary brain-derived neurotrophic factor（BDNF）, an ubiquitous neurotrophin, was found to rise in patients with benign prostatic hyperplasia（BPH）. We hypothesized that the urinary level of BDNF could be a potential biomarker for lower urinary tract symptoms（LUTS） in patients with BPH. Totally, 76 patients with BPH-caused LUTS and 32 male control subjects without BPH were enrolled. International Prostate Symptom Score（IPSS） was applied to assess the symptom severity of LUTS. Urodynamic tests were performed for the diagnosis of underlying detrusor overactivity（DO） in the patients with BPH. Urine samples were collected from all subjects. Urinary BDNF levels were measured using enzyme-linked immunosorbent assays and normalized by urinary creatinine（Cr） levels. Seventy-six BPH patients were divided into moderate LUTS group（n=51, 720） according to the IPSS. Of the 76 BPH patients, DO was present in 34（44.7%） according to the urodynamic test. The urinary BDNF/Cr levels were significantly higher in BPH patients with moderate LUTS（8.29±3.635, P〈0.0001） and severe LUTS（11.8±6.44, P〈0.0001） than normal controls（1.71±0.555）. Patients with severe LUTS tended to have higher urinary BDNF/Cr levels than patients with moderate LUTS（11.8±6.44 vs. 8.29±3.635, P=0.000）. The conditions of BPH with LUTS correlated with elevated urinary BDNF levels, and urinary BDNF levels were even higher in BPH-DO patients. The results of this study have provided evidence to suggest that urinary BDNF level test could evaluate the severity of LUTS in BPH patients, and BDNF level can be used as a biomarker

Evaluation of the tumor angiogenesis in benign prostate hyperplasia and prostatic cancer with MR perfusion-weighted imaging

Objective： To explore the application of MR perfusion-weighted imaging （PWI） in the benign and malignant prostate diseases, and evaluate the correlations of PWl features with vascular endothelial growth factor （VEGF） and microvessel density （MVD）. Methods： Seventy-four consecutive patients who were diagnosed clinically for the prostate diseases, including forty-four cases with benign prostate hyperplasia and thirty cases with prostatic cancer proved pathologically, were examined by PWI. MVD and VEGF were stained with immunohistochemical methods. Some parameters of PWl, including the steepest slope of signal intensity-time curve （SSmax） and the change in relaxation rate （ΔR2^＊ peak） at lesions, were analyzed. Correlation analysis was used to determine the relationship between the results of PWl and immunohistochemistry. Results： （1） In the benign prostate hyperplasia （BPH）, SSmax and ΔR2^＊ peak of perfusion curve were 34.2 ± 2.9 and 1.49 ± 0.11, respectively; however, in the prostatic cancer （Pca）, they were 58.6± 4.8 and 3.18 ±0.49 respectively; there were statistical differences （t = 2.16 and 2.31, P 〈 0.05）. （2） The VEGF and MVD expressions of thirty Pca patients were significantly higher than those of forty-four BPH patients （x2 = 28.64, P 〈 0.01; t = 21.2, P 〈 0.01）. MVD expressions of Pca and BPH groups showed positive associations with VEGF expressions （P 〈 0.01）. On MR perfusion-weighted imaging, SSmax and ΔR2^＊ peak showed associations with MVD and VEGF expressions （P 〈 0.01）. Conclusion： On MR perfusion-weighted imaging, SSmax and ΔR2^＊ peak can reflect MVD and VEGF expression levels in the benign and malignant prostate diseases and might be implied the tumor angiogenesis so as to distinguish benign from malignant and provide the important information for the surgeon to diagnose and treat the prostatic diseases.

Mechanisms of Prostate Atrophy after LHRH Antagonist Cetrorelix Injection: An Experimental Study in a Rat Model of Benign Prostatic Hyperplasia

In the present study, we investigated the roles of TGF-β signaling pathway in a rat benign prostatic hyperplasia （BPH） model treated with cetrorelix. TGF-β1 and c-Myc expression were measured by qRT-PCR and Western blotting in the proximal and distal region of ventral prostatic lobes, respectively. We observed that treatment with cetrorelix led to a significant reduction of ventral prostate weight in a dose-dependent manner. In the proximal region, after cetrorelix treatment, the expression of TGF-β1 was dramatically increased （P〈0.05）, while the expression of c-Myc was significantly decreased （P〈0.05）. In comparison with the control group, the cetrorelix groups had more TUNEL-positive cells. Our findings strongly suggest that the TGF-β signaling pathway may be one of the major causes responsible for prostate volume reduction in BPH rats after cetrorelix treatment.

Hypoxia activates the hypoxia-inducible factor-1α/vascular endothelial growth factor pathway in a prostatic stromal cell line:A mechanism for the pathogenesis of benign prostatic hyperplasia

Background The development of benign prostatic hyperplasia(BPH)is closely related to hypoxia in the prostatic stroma,and the hypoxia-inducible factor-1α/vascular endothelial growth factor(HIF-1α/VEGF)pathway has been shown to significantly activate in response to hypoxia.The underlying mechanism for activation of this pathway in the pathogenesis of BPH remains unclear.Materials and methods We constructed HIF-1αoverexpression and knockdown BPH stromal(WPMY-1)and epithelial(BPH-1)cell lines,which were cultured under different oxygen conditions(hypoxia,normoxia,and hypoxia+HIF-1αinhibitor).Quantitative real-time polymerase chain reaction(qPCR)and Western blotting were applied to detect the expression of the HIF-1α/VEGF pathway.Cell proliferation and apoptosis were analyzed by Cell Counting Kit-8 and flow cytometry.We used the miRWalk 2.0 database and Western blotting to predict the potential miRNA that selectively targets the HIF-1α/VEGF pathway,and verified the prediction by qPCR and dual-luciferase assays.Results In a BPH stromal cell line(WPMY-1),the expression of VEGF was in accordance with HIF-1αlevels,elevated in the overexpression cells and decreased in the knockdown cells.Hypoxia-induced HIF-1αoverexpression,which could be reversed by a HIF-1αinhibitor.Moreover,the HIF-1αinhibitor significantly depressed cellular proliferation and promoted apoptosis in hypoxic conditions,assessed by Cell Counting Kit-8 and flow cytometry.However,in the BPH epithelial cell line(BPH-1),the expression level of HIF-1αdid not influence the expression of VEGF.Finally,a potential miRNA,miR-17-5p,regulating the HIF-1α/VEGF pathway was predicted from the miRWalk 2.0 database and Western blotting,and verified by qPCR and dual-luciferase assay.Conclusions In hypoxia,activation of the HIF-1α/VEGF pathway plays a crucial role in regulating cell proliferation in a BPH stromal cell line.Regulation by miR-17-5p may be the potential mechanism for the activation of this pathway.Regulation of this pathway may be involved in the pathogenesis of BPH.

Stable state of serum inflammatory cytokines during induction of benign prostate hyperplasia in dogs

Objective:To monitor serum inflammatory cytokines during induction of benign prostate hyperplasia in dogs.Methods:This research was designed as a case-control study.There were 20 adult mixed-breed intact male dogs,which were divided into the normal group(n=10)and the benign prostate hyperplasia group(n=10).In the benign prostate hyperplasia group,benign prostate hyperplasia was induced by injection of testosterone(75.00 mg/dog,i.m.)and estrogen(0.75 mg/dog,i.m.)on day 0(day of the first injection),day 21,day 42,and day 63.The doses of testosterone were doubled on days 21,42,and 63.The normal group did not receive any injection.Blood sampling was performed from the jugular vein at days 0,21,42,and 63.The concentrations of interleukin-8,interleukin-10,and tumor necrosis factor-α(TNF-α)were assayed by enzyme-linked immunosorbent assay.Results:The levels of interleukin-8,interleukin-10 and TNF-αwere not significantly different between the normal group and the benign prostate hyperplasia group.Also,concentrations of the pro-inflammatory cutokines were not significantly different between the normal group and the BPH group in each day of sampling.Conclusions:In spite of the induction of benign prostate hyperplasia,changes in the concentration of blood serum inflammatory cytokines were not significantly different with that of the normal group and between the days of induction of benign prostate hyperplasia during two months.It reveals that there is a stable state of serum inflammatory cytokines during induction of benign prostate hyperplasia in dogs.

Periodontal disease and risk of benign prostate hyperplasia: a cross-sectional study

Background:Both periodontal disease and benign prostatic hyperplasia are age-related diseases that affect millions of people worldwide.Hence,this study aimed to investigate the association between periodontal disease and the risk of benign prostatic hyperplasia.Methods:A total of 4930 participants were selected from an available health examination that was carried out in 2017,only males were considered for further analysis.All eligible males were divided into benign prostatic hyperplasia and normal groups,the benign prostatic hyperplasia group was then divided into prostate volume≤60 g and>60 g subgroups;all their periodontal status was extracted and then into normal(CPI score of 0),periodontal disease(CPI score between 1 and 4),and periodontitis(CPI score between 3 and 4)groups.The correlation between periodontal disease and benign prostatic hyperplasia was investigated using logistic regression analyses and greedy matching case-control analysis.Subgroup analysis based on prostate volume was also performed.All analyses were conducted with SAS 9.4 software.Results:A total of 2171 males were selected for this analysis.The presence of periodontal disease significantly increased the risk of benign prostatic hyperplasia by 1.68 times(OR=1.68,95%CI:1.26–2.24),and individuals with periodontitis showed a higher risk(OR=4.18,95%CI:2.75–6.35).In addition,among matched cases and controls,this association remained robust(periodontal disease:OR=1.85,95%CI:1.30–2.64;periodontitis:OR=4.83,95%CI:2.57–9.07).Subgroup analysis revealed that periodontal disease significantly increased benign prostate hyperplasia risk as well(for prostate volume≤60 g:OR=1.64,95%CI:1.22–2.20;for volume>60 g:OR=2.17,95%CI:1.04–4.53),and there was a higher risk in the group with a prostate volume greater than 60 g.Conclusions:Periodontal disease is significantly and positively associated with an increased risk of benign prostatic hyperplasia.Further validation studies should be performed to explore the relationship between periodontal treatment and benign prostate hyperplasia.

老年良性前列腺增生症患者衰弱现状及影响因素的调查研究

目的探讨老年良性前列腺增生症(benign prostatic hyperplasia,BPH)患者的衰弱情况,并对其影响因素进行分析,以期为此类患者的衰弱预防和干预提供有效指导。方法于2023年2—12月在山东大学齐鲁医院住院BPH且≥60岁的患者中选取241例为调查对象。采用自行设计的一般资料信息调查表,通过衰弱指数量表(tilburg frailty indicator,TFI)、微营养评定量表-简表(short-form mini-nutritional assessment,MNA-SF)、蒙特利尔认知评估量表(Montreal cognitive assessment,MoCA)进行问卷调查,采用单因素分析、Pearson相关分析、二元logistic回归分析筛选老年BPH患者衰弱的影响因素。结果在241例老年BPH患者中TFI总得分≥5分的共有146例(60.6%),呈衰弱状态。单因素分析显示,年龄、饮酒、身体质量指数(body mass index,BMI)、个人月收入、慢性病种类、口服药种类数、MNA-SF、MoCA与老年BPH患者是否发生衰弱有关(P<0.05);老年BPH患者TFI总分与MNA-SF呈负相关(r=-0.147,P<0.05),与MOCA呈负相关(r=-0.241,P<0.01);经logistic二元回归分析结果显示,年龄、慢性病种类、MNA-SF、MOCA评分是老年BPH患者衰弱的主要影响因素(P<0.05)。结论老年BPH患者衰弱发生率比较高,高龄、慢性病种类多、MNA-SF及MOCA评分低的老年BPH患者更容易发生衰弱,老年BPH患者衰弱的状态应该引起医护人员的重视,针对该人群应该及时采取有针对性的干预措施,从而达到预防及延缓老年BPH患者衰弱发生发展的目的。

良性前列腺增生患者经尿道前列腺切除术后发生深静脉血栓形成的影响因素分析

目的:探讨良性前列腺增生(BPH)患者经尿道前列腺切除术(TURP)后发生深静脉血栓形成(DVT)的影响因素。方法:回顾性分析2017年1月—2023年5月济南市第一人民医院收治的588例BPH患者的临床资料,根据术后DVT发生与否,将患者分为DVT组和对照组,DVT组104例,对照组484例。对比分析两组患者的性别、年龄、冠心病史等资料,将组间比较有显著差异的变量代入logistic回归进行多因素分析,筛选TURP后发生DVT的影响因素。结果:DVT组脑梗死病史占比、中性粒细胞计数、中性粒细胞-淋巴细胞比值(NLR)、血小板-淋巴细胞比值(PLR)均高于对照组,淋巴细胞计数、血小板-中性粒细胞比值(PNR)均低于对照组,差异均有统计学意义(P<0.05)。多因素logistic回归分析结果显示,脑梗死史(脑梗死恢复期)、中性粒细胞计数、PNR是BPH患者经尿道前列腺切除术后发生DVT的危险因素(P<0.05)。结论:脑梗死恢复期、较高的中性粒细胞计数和较低的PNR可增加BPH患者经尿道前列腺切除术后发生深静脉血栓形成的风险。

良性前列腺增生术后阴茎勃起功能障碍发生风险的列线图模型建立与风险分层

目的探讨良性前列腺增生(BPH)患者术后阴茎勃起功能障碍(ED)发生的风险因素,并建立列线图模型及风险分层标准,为临床防治ED提供参考。方法回顾性分析2021年1月至2023年6月新乡医学院第一附属医院收治的120例BPH术后患者的临床资料,根据术后是否发生ED分组,其中ED组60例,非ED组60例。比较两组患者的临床资料,采用Logistic回归方程分析BPH患者术后ED发生的影响因素,采用R-3.4.5软件语言建立列线图模型,绘制受试者工作特征曲线(ROC)、校准曲线、曲线下面积(AUC)、决策曲线(DCA)分析列线图模型预测效能,采用递归分割法建立ED发生风险分层系统。结果ED组患者中合并高血压、抑郁症、糖尿病、下尿路症状≥2项的例数占比分别为46.67%、31.67%、43.33%、45.00%,明显高于非ED组的28.33%、15.00%、23.33%、25.00%,差异均有统计学意义(P<0.05);ED组患者的一氧化氮(NO)、睾酮(T)水平分别为(40.42±5.56)nmol/mL、(2.11±0.60)μg/L,明显低于非ED组的(46.78±6.12)nmol/mL、(2.72±0.81)μg/L,而内皮素-1(ET-1)水平为(71.88±8.89)ng/L,明显高于非ED组的(60.02±10.23)ng/L,差异均有统计学意义(P<0.05);ED组患者收缩期峰值流速(PSV)、舒张末期流速(EDV)、阻力指数(RI)分别为(7.56±2.27)cm/s、(20.23±3.58)cm/s、0.59±0.17,明显小于非ED组的(10.22±2.69)cm/s、(25.51±4.36)cm/s、0.78±0.23,差异均有统计学意义(P<0.05);Logistic回归分析结果提示,高血压、抑郁症、糖尿病、NO、ET-1、T均是BPH术后ED发生风险的影响因素(P<0.05);基于上述影响因素构建的BPH术后ED发生风险的列线图预测模型的AUC为0.862,95%CI为0.796~0.927;DCA曲线显示该模型具有正向净获益;危险分层分析结果显示,高风险患者ED发生率为85.71%(36/42),高于中等风险的32.56%(14/43)和低风险的28.57%(10/35),差异有统计学意义(P<0.05)。结论高血压、抑郁症、糖尿病、NO、ET-1、T均是BPH术后ED发生风险的影响因素,基于上述影响因素建立的预测模型预测效能较高,基于预测模型的危险分层系统能较好地识别高危险患者,便于指导临床治疗。

服用非那雄胺的前列腺增生患者前列腺转录组景观特征分析

目的通过转录组分析从基因表达方面探讨非那雄胺对良性前列腺增生(BPH)患者的影响。方法收集2020年10月—2021年10月于北京大学第三医院接受前列腺电切术的患者,根据患者术前是否长期(>6个月)服用非那雄胺分为用药组和非用药组,两组各8例。对两组患者的前列腺组织标本进行转录组测序分析,定量聚合酶链式反应(qPCR)及免疫组化分析验证其结果。结果用药组与非用药组相比,上调基因857个,下调基因806个。通路富集分析显示,非那雄胺导致焦点粘附通路中血管内皮生长因子D型(VEGFD)表达下调;组间网络分析提示钙信号通路为整个过程的关键通路;进一步对其进行基因集富集分析(GSEA)发现分化簇38(CD38)基因表达上调。qPCR及免疫组化验证支持上述转录组结果,同时发现雄激素受体表达升高。结论非那雄胺通过下调焦点粘附通路中VEGFD的表达减少前列腺微血管生成,进而降低BPH手术出血的风险,长期服用非那雄胺导致钙信号通路中CD38表达上调,可能与非那雄胺抵抗有关。

前列腺增生患者TUPKRP术后发生全身炎症反应综合征的危险因素分析

目的探讨经尿道前列腺等离子电切术(TUPKRP)患者术后发生全身炎症反应综合征(SIRS)的危险因素,以期为临床决策的制定提供参考。方法收集2019年5月—2022年5月于新疆某医院行TUPKRP手术的170例BPH患者的临床资料,将发生术后SIRS的患者纳入SIRS组,未发生术后SIRS的患者纳入非SIRS组。收集2组患者一般资料、实验室检查结果及围术期指标,采用单因素分析及多因素logsitic回归模型分析TUPKRP术后发生SIRS的危险因素。结果170例接受TUPKRP术治疗的BPH患者中,32例(18.82%)发生术后SIRS。SIRS组和非SIRS组患者在年龄、合并2型糖尿病(T2DM)与否、术前前列腺体积、术前尿路感染与否、术前血白蛋白(Alb)水平、术前血红蛋白(Hb)水平及手术时间方面的差异均有统计学意义(P<0.05);而2组患者在身体质量指数、高血压史、术前国际前列腺症状评分(IPSS)、术前白细胞(WBC)计数、术中出血量及术后尿管留置时间方面的差异均无统计学意义(P>0.05)。logistic回归模型分析结果提示高龄(OR=1.194,95%CI:1.078~1.322),合并T2DM(OR=3.142,95%CI:1.412~6.991),术前前列腺体积大(OR=1.087,95%CI:1.029~1.148)是TUPKRP术后发生SIRS的独立危险因素(P<0.05),术前高Hb水平(OR=0.903,95%CI:0.838~0.973)是TUPKRP术后发生SIRS的独立保护因素(P<0.05)。结论TUPKRP术后SIRS发生率较高,高龄、合并T2DM、术前前列腺体积大是TUPKRP术后发生SIRS的独立危险因素,而术前高Hb水平是TUPKRP术后发生SIRS的独立保护因素。可针对以上相关因素进行相应干预,以减少术后SIRS发生。

老年前列腺增生患者病耻感与家庭关怀度的相关性研究

目的 调查老年前列腺增生(BPH)患者病耻感与家庭关怀度现状,分析病耻感影响因素,探索家庭关怀度与病耻感关系。方法 采用便利抽样法,选取2022年3—12月在安徽医科大学第一附属医院住院的老年BPH患者158例为研究对象,采用一般情况调查表、社会影响量表(SIS)、家庭关怀度指数问卷(APGAR)进行调查。结果 老年BPH患者平均病耻感得分为(53.89±4.93)分、家庭关怀度得分为(7.43±1.27)分,两者呈显著负相关(r=-0.914,P <0.001)。在单因素分析中,年龄、职业、文化程度、月收入、留置尿管、医保类型、曾就诊情况差异有统计学意义(P <0.05)。分层回归分析显示,家庭关怀度可独立解释病耻感总变异的25.0%。结论 老年BPH患者病耻感处于中等水平,受多种因素影响;家庭关怀度对病耻感具有负向预测作用,应采取针对性干预措施,促进患者身心康复。

勃起功能障碍和下尿路症状在良性前列腺增生患者中的合并发生率及危险因素分析

目的:研究勃起功能障碍(ED)和下尿路症状(LUTS)在良性前列腺增生(BPH)人群中的合并发生率及危险因素分析。方法:2020年1月至2023年1月在中南大学湘雅二医院门诊就诊的BPH患者,根据纳入和排除标准确定纳入本研究的对象,收集一般资料和临床资料(包括年龄、身高、体重、腹围、臀围、血压、血常规、肝功能、肾功能、血脂和空腹血糖等),通过问卷调查进行国际前列腺症状评分(IPSS)、生活质量评分(QOL评分)和国际勃起功能指数(IIEF-5)评分。采用SPSS 22.0软件进行数据处理与分析。结果:ED合并LUTS在BPH患者各年龄组发生率分别为45~49岁组36.46%,50~54岁组43.72%,55~59岁组53.66%,60~64岁组69.23%,65~70岁组78.74%。LAP、VAI、TyG、HSI、BMI、WHtR、WHR、TG/HDL-C与IPSS得分呈正相关,与IIEF-5得分呈负相关;HDL-C/TC与IPSS得分呈负相关,与IIEF-5得分呈正相关。结论:ED合并LUTS在BPH患者中的发生率随年龄增加而增高,高血压、血脂异常、糖尿病、身高体重指数(BMI)、生活方式可能是ED合并LUTS发生的危险因素,LAP、VAI、TyG、HSI、BMI、WHtR、WHR、TG/HDL-C可有效评估ED合并LUTS在BPH患者中发生的风险。

改良钬激光前列腺剜除术治疗良性前列腺增生患者的疗效及其影响因素分析

目的观察改良钬激光前列腺剜除术(HoLEP)治疗良性前列腺增生(BPH)患者的临床疗效并分析其影响因素。方法回顾性选取96例行改良HoLEP的BPH患者临床资料,设为研究组,另外选取同期行常规HoLEP的BPH患者80例设为对照组。比较研究组和对照组患者的手术指标与临床疗效。根据研究组患者临床疗效进一步将其分为有效组与无效组,采用单因素及多因素Logistic回归分析探讨改良HoLEP对BPH患者临床疗效的影响因素。结果研究组患者术中出血量少于对照组,膀胱冲洗时间及住院时间短于对照组(P<0.01)。术后3个月末,两组患者国际前列腺症状评分(IPSS)、残余尿量较术前降低,最大尿流率较术前升高,且研究组优于对照组(P<0.05或0.01)。96例患者经改良HoLEP术治疗后,术后有效组患者共82例,有效率为85.42%。有效组患者合并糖尿病、术前IPSS、术前残余尿量及前列腺突入膀胱程度均低于无效组,逼尿肌收缩力高于无效组(P<0.05或0.01)。多因素Logistic回归分析显示,合并糖尿病、术前残余尿量、前列腺突入膀胱程度及逼尿肌收缩力是行改良HoLEP治疗BPH患者临床疗效的独立影响因素(P<0.05或0.01)。结论改良HoLEP治疗BPH患者的临床疗效显著,能有效改善临床症状,术中出血少,且利于患者术后恢复,其中糖尿病、术前残余尿量、前列腺突入膀胱程度及逼尿肌收缩力为改良HoLEP治疗BPH患者临床疗效的独立影响因素,建议术前予以重点关注。

前列舒通胶囊联合索利那新治疗老年良性前列腺增生合并膀胱过度活动症术后疗效及其影响因素分析

目的探讨前列舒通胶囊联合索利那新治疗老年良性前列腺增生(BPH)合并膀胱过度活动症(OAB)术后的临床疗效,并分析影响疗效的相关因素。方法回顾性选取医院泌尿外科2020年3月至2023年3月收治的老年BPH合并OAB患者102例,根据用药方案的不同分为对照组(49例)和观察组(53例)。两组患者均口服琥珀酸索利那新片,观察组患者加用前列舒通胶囊,均连续治疗2个月。比较两组患者的总有效率,以及最大尿流率(Qmax)、残余尿量(PVR)、国际前列腺症状评分(IPSS)、BPH生活质量(BPHQOL)评分、OAB症状量表(OABSS)评分。采用单因素方差分析影响前列舒通胶囊治疗老年BPH合并OAB术后疗效的相关因素,并采用多因素Logistic分析其独立危险因素。结果观察组总有效率为90.57%,显著高于对照组的71.43%(P<0.05)。治疗后,两组患者Qmax显著升高,PVR显著降低,IPSS评分、BPHQOL评分、OABSS评分均显著降低(P<0.001),且观察组显著优于对照组(P<0.01)。观察组和对照组患者不良反应发生率相当(32.08%比40.82%,P>0.05)。单因素方差分析结果显示,术前IPSS评分、OABSS评分、前列腺体积、PVR与术中出血量均为影响前列舒通胶囊疗效的相关因素(P<0.05)。多因素Logistic回归分析结果显示,术前前列腺体积、IPSS评分与PVR为独立危险因素(P<0.05)。结论前列舒通胶囊联合索利那新治疗老年BPH合并OAB术后的临床疗效较好,可有效改善患者生活质量。术前前列腺体积、IPSS评分与PVR对老年BPH合并OAB患者的临床疗效有一定预测价值。

良性前列腺增生患者行经尿道切除术后发生尿路感染相关危险因素调查与防护措施分析

目的分析良性前列腺增生(BPH)患者行经尿道切除术(TURP)后发生尿路感染相关危险因素与防护措施。方法选择于我院行TURP的80例BPH患者,根据尿路感染发生情况分为两组,分析BPH患者行TURP术后发生尿路感染的危险因素,并制定防护措施。结果80例BPH患者中有15例患者发生术后尿路感染。单因素分析显示,感染组术前进行导尿术、合并糖尿病、术前未使用抗生素、导尿管留置时间>5 d占比均高于未感染组(P<0.05)。Logistic回归分析结果显示,术前进行导尿术、合并糖尿病、术前未使用抗生素、导尿管留置时间>5 d是BPH患者行TURP术后发生尿路感染的独立危险因素(OR>1,P<0.05)。结论BPH患者TURP术后易发生尿路感染,术前进行导尿术、合并糖尿病、术前未使用抗生素、导尿管留置时间>5d是其独立危险因素,及时制定防护措施可减少尿路感染发生。

保留前叶的经尿道前列腺等离子剜除术对BPH患者的疗效及术后尿失禁发生率的影响

目的 分析保留前叶的经尿道前列腺等离子剜除术(PKEP)对前列腺增生症(BPH)患者的疗效及术后尿失禁发生率的影响。方法 选取2020年11月至2022年11月该院收治的80例BPH患者按照不同手术治疗方式分为试验组(43例)及对照组(37例)。对照组给予经尿道双极等离子前列腺电切术(PKRP)治疗,试验组给予保留前叶的PKEP治疗,对比两组患者手术时间、术中出血量、留置导管时间、住院时间、术后尿失禁发生率,以及术前及术后国际前列腺症状评分(IPSS)、残余尿量(RUV)、最大尿流率(Qmax)、血清睾酮(T)、前列腺特异性抗原(PSA)、前列腺素E_(2)(PGE_(2))水平及健康状态调查表(GQOL-74)评分。结果 试验组术中出血量少于对照组,手术时间、留置导管时间、住院时间短于对照组,差异均有统计学意义(P<0.05)。术后两组IPSS、RUV、T、PGE_(2)、PSA水平低于术前,且试验组低于对照组,差异均有统计学意义(P<0.05)。术后两组心理功能、社会功能、躯体功能、物质生活维度的GQOL-74评分及Qmax高于术前,且试验组高于对照组,差异均有统计学意义(P<0.05)。试验组术后1周尿失禁的总发生率低于对照组(P<0.05)。结论 与PKRP治疗相比,采用PKEP治疗BPH患者的术中出血量更少,手术创伤更小,术后恢复情况更优,以及更能改善尿流动力学,降低术后尿失禁发生率,提高患者生活质量。

良性前列腺增生术后泌尿系统感染患者性功能障碍发生情况及其影响因素分析

目的分析良性前列腺增生术后泌尿系统感染患者性功能障碍发生情况及其影响因素。方法选取2020年1月至2023年1月儋州市人民医院泌尿外科收治的475例良性前列腺增生术后泌尿系统感染患者作为研究对象。收集患者基线资料、实验室指标;采用国际勃起功能指数-5(IIEF-5)、症状自评量表(SCL-90)评估患者性功能障碍及焦虑、抑郁情况。根据IIEF-5评估标准将患者分为障碍组与正常组,采用Logistic回归分析良性前列腺增生术后泌尿系统感染患者发生性功能障碍的影响因素。结果术后3个月,475例患者中98例评估为性功能障碍(障碍组),占20.63%;两组糖尿病史占比、高血压史占比、睾酮水平、一氧化氮(NO)水平、伴焦虑占比及伴抑郁占比比较,差异具有统计学意义(P<0.05);多因素Logistic回归分析显示,糖尿病史、高血压史、睾酮及NO水平下降、伴焦虑、伴抑郁是良性前列腺增生术后泌尿系统感染患者性功能障碍的影响因素(P<0.05)。上述指标联合预测性功能障碍的曲线下面积为0.897(95%CI:0.863~0.931),具有一定的预测价值。结论良性前列腺增生术后泌尿系统感染患者部分伴有性功能障碍,糖尿病史、高血压史、睾酮及NO水平下降、负面情绪是发生性功能障碍的影响因素,临床可针对相关因素加强干预,以便降低性功能障碍的发生风险。